MedTrace Logo

XM-One Study for Living Donor Program

NCT01679184 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2015-11-13

No results posted yet for this study

Summary

Donor-Specific Antibody (DSA) (HLA) levels and non-HLA antibody levels in recipients prior to living kidney transplantation and randomize these individuals into a desensitization protocol in order to evaluate shifts that can occur with the Luminex and XM-One assay after treatment and up to 6 months post transplant.

If desensitization is needed prior to transplantation in individuals with a negative crossmatch but positive DSA and/or XM-one - patients will be evaluated clinically with routine lab tests (serum creatinine levels, spot urine protein and spot urine creatinine levels) as well as protocol biopsy evaluations.

Conditions

  • Transplant; Failure, Kidney

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Giselle Guerra, R.N. · University of Miami

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01679184 on ClinicalTrials.gov